Sanofi和Orano Med合作开发用于稀有癌症的铅212放射性核素和药品。 Sanofi and Orano Med collaborate to develop lead-212 radioligand medicines for rare cancers.

Sanofi和Orano Med合作开发下一代针对罕见癌症的放射病药品。 Sanofi and Orano Med have partnered to develop next-generation radioligand medicines targeting rare cancers. 合作将在Orano Med品牌下设立一个新实体,重点是使用铅-212α排放同位素进行治疗。 The collaboration will establish a new entity under the Orano Med brand, focusing on therapies using lead-212 alpha-emitting isotopes. 这一举措遵循一项与放射疗法(包括阿尔法梅迪克斯项目)有关的独家许可协议,目的是加强难以治疗癌症的治疗选择,同时支持法国2030年肿瘤创新目标。 This initiative follows an exclusive licensing agreement related to radioligand therapies, including the AlphaMedix project, and aims to enhance treatment options for difficult-to-treat cancers while supporting France's 2030 oncology innovation goals.